Posters

Retrospective audit examining visual and anatomical outcomes in patients post use of intravitreal ocriplasmin for symptomatic vitreomacular traction

Poster Details

First Author: P.Murtagh IRELAND

Co Author(s):    K. Frank                             

Abstract Details



Purpose:

To determine whether a single intravitreal injection of 0.125 mg Ocriplasmin would improve symptoms, vision and anatomical (as determined by spectral domain OCT) outcomes in patients with symptomatic vitreomacular traction and determine outcomes 2.5 years post injection.

Setting:

Department of Ophthalmology, University Hospital Galway, Republic of Ireland

Methods:

A retrospective audit was undertaken to examine endpoints such as visual acuity, OCT anatomy and symptoms in patients before and after intravitreal injection of 0.125mg of Ocriplasmin for symptomatic vitreomacular traction. VA was recorded in the patient’s medical record in Snellen and converted to LogMAR and a pre and post injection OCT was recorded using the Heidelburg OCT Spectralis and anatomical outcomes were compared. Follow up was as far as 2.5 years post injection.

Results:

A total of 30 eyes of 29 patients were included in the study spanning a 2.5 year period and involved every patient that had an Ocriplasmin injection in our unit. Symptomatic viteromacular traction was confirmed by OCT alongside a documented decrease in visual acuity ± visual distortion. OCT was taken on average 27.4 days post procedure. An overall response rate of 63.3% was determined by resolution of traction on OCT and an increase in LogMAR VA. Those that did not experience resolution (11/30 eyes) were had no change in OCT findings. Patients who displayed all or some of the positive predictive markers i.e. no epiretinal membrane (ERM) at baseline, VMA diameter ≤1500 µm, younger than 65 years of age and phakic lens status, were shown to have a higher rate of anatomical success. Side effects of injections were also recorded.

Conclusions:

Our cohort of 30 eyes is one of the larger cohorts of patients examinable post intravitreal ocriplasmin. A success rate of 63.3% is favourable especially when compared to the cost and potential complications of vitreoretinal surgery. The improvement in vision and release in traction is at times associated with transient changes in retinal anatomy. Long-term outcomes have yet to be determined but a follow up of 2.5 years in some of patients has proven favourable.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy